3D printing, also known as Additive Manufacturing (AM), has attracted increasing interest during the last decade and is used in numerous industries including, construction, aerospace, food, and manufacturing.
In the past few years, 3D printing has gained interest in medicine and tissue engineering applications. It has led to significant advances in the healthcare sector — 3D bioprinting, especially regenerative medicine that facilitates on-demand printing of cells, tissues, and organs.
3D bioprinting is considered an effective alternative for existing organ transplantation methods due to ongoing demands and the lack of adequate organ donors.
According to various experts, research groups in several countries as China, United State, South Korea, The Netherlands, and Singapore, besides others, have been investing strongly in the bioprinting area.
Raised €1.2M funding
Turku-based bioprinting startup Brinter, a spin-off from 3DTech Ltd, is the latest company to get funding. The Finnish startup has raised €1.2M funding in Seed Round led by early-stage VC Innovestor.
The company will use the capital to further expand its operations internationally in Europe and the US. It’s worth mentioning that Brinter has bootstrapped its growth since 2019 when it launched its first product.
Based out of Helsinki, Innovestor is an early-stage venture capital investor with a total of €123M across three funds.
The VC currently manages one of the largest private venture-backed portfolios in the Nordics, consisting of over 100 high-tech companies in multiple fields such as cleantech, consumer, enterprise software, health, industrial technologies, and life science.
Bioprinting within reach
Brinter is a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company claims is on a mission to put bioprinting within reach of every pharmaceutical company, hospital, university, and research centre.
The company provides 3D bioprinting solutions and services for pharmaceutical, biotechnological and cosmetic industries, universities, and research facilities.
Brinter seeks to save more lives through more personalised treatment and the production of “spare parts” such as hearts and kidneys.
We are excited to have the backing of Innovestor, who can help us accelerate the development of our operational capabilities and scale in new geographies,” says Brinter CEO Tomi Kalpio.
“Bioprinting can rapidly unlock the opportunities behind long-running but unrealised science and research and plays a key role in pushing the frontier of medical science. This will result in an improved quality of life for patients through the expansion of more personalised treatment and the ongoing development of bioprinted “spare parts” that can save lives,” he explains.
Brinter is active in over ten countries and serves organisations such as Nanoform, as well as research organisations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki.